Tricellular Adipose Regeneration Units in pGelMA Hydrogel Synergistically Enhance Fat Graft Survival through Vascularization and ECM Remodeling.
Liu E., Li Y., Wang P., Wang X., Gao Z.
Animal Study, published in ACS Biomater Sci Eng (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- ACS Biomater Sci Eng (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41159860
- DOI
- 10.1021/acsbiomaterials.5c01484
Abstract (original English)
Autologous fat transplantation (AFT) remains limited by low graft survival rates due to insufficient vascularization and extracellular matrix (ECM) support. Here, we developed an adipose tissue regeneration unit (ATRU) system combining three key cellular components (adipose-derived stem cells, ADSCs; human umbilical vein endothelial cells, HUVECs; and fibroblasts, FBs) within a porous gelatin methacryloyl (pGelMA) hydrogel microenvironment. Through controlled coculture in microwell plates, this system generated functional microtissues, demonstrating synergistic effects: ADSCs provided adipogenic potential; HUVECs enabled vascular network formation, and FBs facilitated ECM deposition. Comprehensive in vitro characterization confirmed enhanced cell viability, adipogenic differentiation, and collagen production. In vivo implantation in nude mice revealed enhanced performance of ATRU constructs compared to ADSC-only controls, with histological and immunohistochemical analysis showing: (1) a 1.14-fold increase in adipose tissue area, (2) a 1.55-fold increase in the number of CD31 + blood vessels per field of view, and (3) substantially elevated type III collagen deposition. The incorporation of pGelMA provided a biocompatible and porous scaffold, facilitating cell viability, nutrient diffusion, and structural integration with the host tissues. These results highlight the capacity of
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.